If you are interested in learning more about one of our ongoing clinical trials, please feel free to call our Clinical Research Program at 520-320-2147.
Alzheimer’s Disease Clinical Trial – Now Enrolling
This study is comparing the effects of an investigational drug versus placebo on participants and their memory problems.
Glioblastoma Clinical Trial – Now Enrolling
This study will help us learn more about a newly discovered vaccine drug that is being tested in people with recurrent or progressive glioblastoma, who have already received treatment.
Learn more at ClinicalTrials
Identifier (NCT): NCT03276286
Novartis ARTIOS Study
The purpose of this study is to see if a medication called ofatumumab is safe and works in adults with relapsing multiple sclerosis (MS) who switch from their current oral medication. Ofatumumab has been studied in people living with MS and has been shown to reduce relapses, MRI lesions and disability worsening.
To be considered for the clinical study, you must be 18 to 60 years old, have a relapsing form of MS, and have disease breakthrough activity—like a confirmed relapse or MRI lesions—while taking oral medicine dimethyl fumarate or fingolimod for at least six months. The length of the study is approximately two years.
If you, a family member or loved one wants to learn more about participating in this study, please contact the ARTIOS study coordinator at (520) 320-2157.
Roche Fenhance Study
Relapsing multiple sclerosis (RMS) affects approximately 85% of people with MS. While many treatments have been approved for the condition, there is an unmet need for a treatment that can reduce disability progression and disease activity. That’s why we’re conducting the FENhance 1 (GN41851) study. The FENhance 1 study assesses how safe and effective an investigational study drug is in treating RMS, compared to an approved comparator drug (a drug that is already being used to treat patients with RMS).
The investigational study drug works by suppressing the production of B cells that attack healthy nerve cells in people with RMS. Among other things, participants must be aged between 18 and 55 and diagnosed with RMS with an EDSS score of between 0 and 5.5.
The total length of the trial is at least two years (including screening and follow-up), during which time participants will be randomly assigned to receive either the investigational study drug (50% chance) or the approved comparator drug (50% chance).
Participants who join the study must visit a study clinic at least 15 times over two years (unless for any reason they leave the study early) so that we can monitor their general health and condition with assessments such as blood tests, urine tests, physical examinations, MRIs, neurological examinations and questionnaires. They will also have telephone interviews approximately every six weeks between study visits.
If you think this study might be right for you or if you would like more information, please contact the FENhance Study Coordinator by calling 520-320-2147 . They’ll be happy to tell you more.
Roche Gavotte Study
We’re looking for people between ages 18 and 55 who are diagnosed with PPMS to join this study. You must have an Expanded Disability Scale (EDSS) score of between 3.0 and 6.5 inclusive. This is a measure of how much your condition affects you—your current MS doctor will be able to tell you yours. If you participate, you’ll be randomly assigned either an investigational higher dose of Ocrelizumab (two-thirds of participants will receive this) or the approved dose (one-third of participants will receive this).
If you, a family member or loved one is interested in learning more about participating in this study, please contact the Gavotte study coordinator at 520-795-0229.
CND/NIH Synuclein-One Study
The Synuclein-One Study is seeking men and women 40-99 years old with a clinical diagnosis of Parkinson’s disease, multiple System Atrophy, Dementia with Lewy Bodies, or Pure Autonomic Failure. You won’t be able to participate if you use blood thinners (but Plavix or aspirin alone is allowed).
If you, your family member or loved one is interested in learning more about participating in this study, please contact the Synuclein-One Study Coordinator at (520) 320-2157.
Eli Lilly TRIUMPH Study
The TRIUMPH Study will involve about 2,850 people who have migraine headaches and who are starting a new medication to prevent migraine. The study will look at how well commonly prescribed migraine prevention medications work.
This observational research will collect information about your medical condition, your routine care, and the medications you have been prescribed. There are no investigational drugs being tested. The study doctor will try to collect all necessary information at the same time as your routine appointments.
You may be able to take part if you are 18 years of age or older, have been diagnosed with migraine, are starting a migraine prevention medication or switching to a different one, and have access to the internet on a computer or your mobile phone.
If you, your family member or loved one wants to learn more or participate in this study, please contact the TRIUMPH study coordinator at (520) 320-2157.